Bdenza 80mg capsule

It is advised to use Bdenza 80 mg capsule as directed by the doctor. The common side effects of this tablet are:
Trouble breathing (pneumonia) feeling tired Back pain diarrhoea cold headache insomnia high blood pressure swelling in arms, legs, feet, or hand

It is advised to use Bdenza 80 mg capsule as directed by the doctor. The common side effects of this tablet are:
Trouble breathing (pneumonia) feeling tired Back pain diarrhoea cold headache insomnia high blood pressure swelling in arms, legs, feet, or hand

Bdenza 80 mg capsules should always be taken as prescribed by a doctor; they are not meant for self-medication. It can be taken with or without food as directed by the doctor. For optimal medication effectiveness, Bdenza 80 mg capsules must be swallowed rather than chewed, opened, or crushed. It is an oral medication used once a day at the same time every day, before meals. The Bdenza 80 mg capsule should be taken with at least an hour gap interval.

Akaza, H., Uemura, H., Tsukamoto, T., Ozono, S., Ogawa, O., Sakai, H., & Naito, S. (2024). A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. International Journal of Clinical Oncology, 21(4), 773-782.
Golshayan, A. R., & Antonarakis, E. S. (2023). Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core evidence, 27-35.
Hori, A., Sahashi, H., Sano, S., Matsumiya, E., Ariga, M., Asano, A., & Kitaichi, K. (2020). Efficacy and safety of enzalutamide in a real-world cohort of Japanese patients with castration-resistant prostate cancer. Anticancer Research, 40(12), 7101-7108.
Miura, R., Hirabatake, M., Irie, K., Ikesue, H., Muroi, N., Kawakita, M., & Hashida, T. (2021). Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. In Urologic Oncology: Seminars and Original Investigations (Vol. 39, No. 4, pp. 233-e15). Elsevier.
Vinh-Hung, V., Natchagande, G., Joachim, C., Gorobets, O., Drame, M., Bougas, S. & Yin, M. (2020). Low-dose enzalutamide in late-elderly patients (≥ 75 years old) presenting with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 18(6), e660-e668.